On October 23, 2026, biotech company Star Therapeutics announced a $200 million private financing round co-led by OrbiMed and Janus Henderson Investors. Following the $2 billion sale of its subsidiary Vega Therapeutics to Incyte in July 2026 and the $350 million IPO of spinout Electra Therapeutics in September 2026, Star Therapeutics is resetting as an early-stage biotech entering stealth mode to advance its preclinical hematology and immunology pipeline into clinical trials.
Star Therapeutics raises $200 million financing round
- ▪Star Therapeutics announced a $200 million private financing round on October 23, 2026.
- ▪The $200 million private financing round for Star Therapeutics was co-led by OrbiMed and Janus Henderson Investors.
- ▪Investors participating in Star Therapeutics' $200 million financing round included RA Capital Management, Sofinnova Investments, Agent Capital, Catalio Capital Management, Cormorant Asset Management, New Leaf Venture Partners, NYBC Ventures, Redmile, Soleus Capital, and a sovereign wealth fund.
Star Therapeutics shifts strategy and pipeline focus
- ▪Star Therapeutics is shifting away from its initial hub-and-spoke model of creating individually branded spinout companies, choosing instead to operate under the single Star Therapeutics brand.
- ▪Star Therapeutics is focusing on developing new, hard-to-replicate molecules for areas of unmet medical need rather than developing standard-of-care treatments or derivative drugs.
- ▪Star Therapeutics CEO Adam Rosenthal stated that the $200 million financing effectively resets Star Therapeutics as an early-stage biotech that will enter stealth mode to focus on drug discovery.
- ▪Star Therapeutics plans to use the $200 million financing to advance its preclinical experimental biologics targeting rare hematological and immunological conditions into clinical trials.
Recent spinout and acquisition successes
- ▪In September 2026, Star Therapeutics' spinout company Electra Therapeutics became a publicly traded company on Nasdaq under the ticker symbol ETRA.
- ▪In July 2026, Incyte completed the acquisition of Star Therapeutics' wholly owned subsidiary Vega Therapeutics in a transaction valued at up to $2 billion.
- ▪Electra Therapeutics raised $350 million in its September 2026 initial public offering while developing an experimental drug for secondary hemophagocytic lymphohistiocytosis.
- ▪Incyte's acquisition of Vega Therapeutics included Star Therapeutics' lead program latarcibart (VGA039), a novel monoclonal antibody in Phase 3 development for von Willebrand disease.
Track record of team members
- ▪Members of the Star Therapeutics team have invented four first-in-class therapies in Phase 3 development or commercialized, including Enjaymo for cold agglutinin disease.
- ▪Members of the Star Therapeutics team have contributed to four successful acquisitions: Vega Therapeutics, DICE Therapeutics, True North Therapeutics, and iPierian.
Story comments
Loading comments…